Evidence map›Paper›PMID 40341654›Full record

ReviewProstate cancer and prostatic diseases2026

Ultra-hypofractionation for node-positive prostate cancer: pushing boundaries and redefining standards.

Jennifer Le Guévelou, Mathilde Jeandin, Antonio Angrisani, Davide Giovanni Bosetti, Mohamed Shelan, Thomas Zilli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jennifer Le GuévelouLaboratoire de traitement du signal et de l'image, Rennes University, Rennes, France.ORCID http://orcid.org/0000-0002-9589-4873
Mathilde JeandinDepartment of Geriatry, Geneva University Hospital, Geneva, Switzerland.
Antonio AngrisaniDepartment of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.
Davide Giovanni BosettiDepartment of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-2654-1281
Mohamed ShelanDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-6477-6655
Thomas ZilliDepartment of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland. Thomas.Zilli@eoc.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy is a cornerstone in the management of node-positive prostate cancer. Advances in imaging modalities and radiation therapy techniques have led to the evolution of treatment standards for this patient population. This review aims to explore the therapeutic advancements of the past decade, with a focus on the role of ultra-hypofractionated radiotherapy in node-positive prostate cancer.

Indexed as

Lymph NodesProstatic NeoplasmsRadiation Dose HypofractionationHumansLymphatic MetastasisMale

Identifiers

PMID40341654
PMCPMC12909117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.